Assessment of remission maintenance effect of leukocytapheresis for ulcerative colitis

Assessment of remission maintenance effect of leukocytapheresis for ulcerative colitis - Assessment of remission maintenance effect of leukocytapheresis for ulcerative colitis

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008905

Enrollment

Registered

2012-09-13

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Patients treated with leukocytapheresis more than once per week, total 5 sessions. Patients treated with leukocytapheresis more than once per week, total 10 sessions.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with refractory (steroid resistant or steroid dependent), active ulcerative colitis. 2. More than moderate active ulcerative colitis.

Exclusion criteria

Exclusion criteria: 1. Patients under 18 y.o. 2. Patients with either white blood cell count of less than 3,000/mm3, or platelet count of less than 100,000/mm3. 3. Patients with allergic anamnesis or experience or the fear of allergic hypersensitivity reaction. 4. Patients with serious infection or cardiovascular disease or liver disease or kidney disease or respiratory disease or metabolic disease neurologic disease. 5. Patients having received inhibitor of angiotensin converting enzyme. 6. Patients with hypotension (less than maximal blood pressure 80mmHg) 7. Patients who are pregnant or possibly pregnant.

Design outcomes

Primary

Measure	Time frame
Duration of remission maintained (days)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026